Lab Protocol Article Template

Title	Performance comparison of stress hyperglycemia ratio for predicting fatal outcomes in patients with thrombolyzed acute ischemic stroke
Metadata	One file is named 'data set' and is in Microsoft Excel Worksheet (.xlsx) format, containing data collected from January 1, 2015, to July 31, 2022, at Saraburi Hospital in Thailand. The file was last updated on February 7, 2023.
Funding	The authors have a specific grant (MC012-2566, 2023) for this research from Medical Education Center, Saraburi Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."
Competing interests	The authors have no conflicts of interest directly relevant to the content of this article.
Data availability This should include, where applicable, links to data and code produced by the protocol or necessary to interpret the outputs.	Data available on request from the authors.
Associated content Minimum include DOI for protocol on protocols.io	https://doi.org/10.17605/OSF.IO/RYKZA.
Abstract	**Background:** The stress hyperglycemia ratio (SHR), a newly developed metric, is used to assess adverse outcomes in patients with acute ischemic stroke (AIS). However, the relationship between SHR and fatal outcomes (in-hospital mortality [IHM], malignant cerebral edema [MCE], and symptomatic intracerebral hemorrhage [sICH]) in AIS patients receiving recombinant tissue plasminogen activator (rt-PA) treatment is unclear, and determining the optimal threshold remains incomplete. **Materials and Methods:** We retrospectively enrolled a total of 345 AIS patients treated with rt-PA during 2015–2022 and collected data on various glucose metrics, including different types of SHR, glycemic gap (GG), random plasma glucose (RPG), fasting plasma glucose (FPG), and hemoglobin A1c (HbA1c). SHR and GG were calculated using these equations: SHR1, [FPG]/[HbA1c]; SHR2, [admission RPG]/[HbA1c]; SHR3, FPG/[(1.59 × HbA1c)−2.59]; SHR4, [admission RPG]/[(1.59 × HbA1c)−2.59]; GG, admission RPG − [(1.59 × HbA1c)−2.59]. We used multivariable logistic regression analysis (MVLR) to identify the association between different glucose metrics and fatal outcomes after thrombolysis.

| Introduction | Stroke is a prevalent neurological condition and a primary global cause of death, resulting in approximately 6 million annual fatalities [1]. Stroke is the leading cause of death in Thailand, accounting for over 250,000 new cases and 50,000 annual fatalities [2]. Recombinant tissue plasminogen activator (rt-PA) is recommended as a safe and effective treatment [3]. Elevated blood sugar in 40-50% of acute stroke patients may exacerbate ischemic injury through heightened oxidative stress, endothelial dysfunction, and impaired fibrinolysis, resulting in larger infarctions, worse clinical outcomes, and increased mortality rates. [4-5]. Stress hyperglycemia (SH) refers to transient hyperglycemia in the context of illness accompanied by diabetes mellitus (DM) or non-DM. Recently, Roberts et al. [6] introduced the stress hyperglycemia ratio (SHR) to evaluate SH. Hemoglobin A1c (HbA1c), a stable indicator, was used to assess glycemic management in DM patients over three months. SHR is calculated by dividing the admission glucose concentration by the estimated average glucose concentration derived from HbA1c [7]. Different studies employed the glucose/HbA1c ratio to define SHR, aiming for its practical use in clinical settings [8-10].

Poor outcomes and symptomatic intracerebral hemorrhage (sICH) in acute ischemic stroke (AIS) patients treated with rt-PA were associated with hyperglycemia. According to the American Diabetes Association, patients were classified as DM, newly diagnosed DM, or experiencing transient hyperglycemia during hospitalization. The definition of SH remains unclear, but an abrupt increase in plasma glucose levels above the average blood glucose level serves as a reliable indicator [6,11]. Two types of biological markers for SH, SHR and glycemic gap (GG), have been developed to represent SH [11]. Recently, the SHR, a ratio of plasma glucose level to HbA1c, has emerged as a prognostic biomarker for poor outcomes in AIS patients receiving rt-PA treatment.

Although different SHR equations effectively predicted unfavorable outcomes or critical illness in AIS patients [12], the optimal threshold of SHR for assessing SH and predicting fatal outcomes (in-hospital mortality [IHM], malignant cerebral edema [MCE], and sICH) has not been definitively confirmed. Limited data currently exists regarding the comparative predictive value of various types of SHR, GG, absolute plasma glucose, and |

	HbA1c in predicting fatal outcomes in AIS patients treated with rt-PA. Hence, this study aims to explore the predictive performance, optimal thresholds, and association between these variables in predicting fatal outcomes.
Materials and Methods	**Study population** We conducted a retrospective observational cohort study by collecting data on 345 AIS patients who were treated with intravenous rt-PA at Saraburi Hospital, a stroke referral center of a provincial hospital in Thailand, between January 1, 2015 and July 31, 2022. Treatment involved administering intravenous rt-PA following the 2019 AIS management guideline [13]. Inclusion criteria: (1) age $\geq$ 18 years; (2) AIS within 4.5 hours of the last known normal; (3) acute anterior circulation ischemic stroke; and (4) rt-PA treatment only. Exclusion criteria: (1) minor stroke; (2) pregnancy; (3) ICH or infarction > 1/3 the middle cerebral artery (MCA) territory; (4) referred patients with unattainable follow-up; (5) missing data: National Institutes of Health Stroke Scale (NIHSS), non-contrast computed tomography (NCCT) imaging, and laboratory results. Our study did not include AIS patients undergoing EVT due to the study period not being fully reimbursed by Thailand's public health coverage, resulting in difficulty accessing EVT treatment. Data comprising clinical and imaging information were retrieved from our electronic medical records, with diagnoses established using the International Classification of Diseases, 10th Revision codes (I63). The data were fully anonymized before we accessed them, and the ethics committee waived the requirement for informed consent. We don't collect patient-identifying information, including hospital numbers, admission numbers, identity card numbers, or birthdates. The study received ethical approval from the human research ethics committee of Saraburi Hospital on January 30, 2023 (Certificate No. EC004/2566). We accessed the data for research purposes on February 5, 2023. **Data collection** Demographic data, encompassing age, gender, initial clinical presentation, medical history, laboratory investigations, time from symptom onset to treatment, admission blood pressure, Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, and neuroimaging results, were collected. The extent of early ischemic changes was evaluated using the Alberta Stroke

Program Early Computed Tomography Score (ASPECTS). Certified neurologists utilized NIHSS to evaluate stroke severity upon admission. Functional outcome was assessed at the time of hospital discharge using the modified Rankin Scale (mRS), with stroke-certified registered nurses responsible for conducting the assessment. The plasma glucose level on admission was measured before thrombolytic treatment. The history of DM was established by reviewing the patient's medical diagnosis and their antidiabetic drug usage record.

Collection and processing of blood samples and laboratory tests

✓ *Patient preparation*

We collected fasting plasma glucose (FPG) and HbA1c after an 8-14 hour fasting but not exceeding 16 hours, to avoid starvation, with a morning collection between 6:00 a.m. and 10:00 a.m. Random plasma glucose (RPG) was measured upon hospital arrival regardless of the time since the last meal.

✓ *Methods for collecting and submitting specimens*

Blood collection tubes with anticoagulants like sodium fluoride/potassium oxalate were used to collect 2 cc of blood for plasma glucose testing, and tubes with ethylene diamine tetra acetate were used for HbA1c testing. The samples were analyzed within 45 minutes of collection, with results reported within 1 hour. Blood samples for plasma glucose were analyzed using an automated analyzer (Beckman Coulter DxC 700 AU) with the Beckman Coulter glucose reagent. Blood samples for HbA1c were analyzed using an automated analyzer (Mindray BS-820M) with the HbA1c reagent.

We collected data on various glucose metrics, including different types of SHR, GG, absolute blood glucose (RPG and FPG), and HbA1c. SHR and GG were calculated using the following equations: SHR1 [14], [FPG (mmol/L)]/[HbA1c (%)]; SHR2 [15], [admission RPG (mmol/L)]/[HbA1c (%)]; SHR3 [12], FPG (mmol/L)/[(1.59 × HbA1c)−2.59]; SHR4 [16], [admission RPG (mmol/L)]/[(1.59 × HbA1c)−2.59]; and GG [17], admission RPG − [(1.59 × HbA1c)−2.59]. In this study, both the treating physicians and nurses were not involved in measurement the SHR and GG values.

	Outcomes assessment The primary outcome of the study was IHM defined as patients with thrombolyzed AIS who died in the hospital. The secondary outcomes were MCE and sICH. The diagnostic criteria for malignant cerebral edema (MCE) were as follows: (i) acute complete MCA infarction with parenchymal hypodensity covering at least 50% of the MCA territory, along with sulcal effacement and lateral ventricle compression; (ii) excessive midline shift exceeding 5 mm and obliteration of basal cisterns; and (iii) neurological deterioration was characterized by an increase in NIHSS score (more than 2 points) and a decline in consciousness level (at least 1 point in item 1A of the NIHSS assessment) [18]. Based on the National Institute of Neurological Disorders and Stroke criteria, sICH was defined as any deterioration in NIHSS score or mortality within 7 days of thrombolysis initiation, along with the presence of any type of intracerebral hemorrhage on posttreatment imaging. [19]. NCCT scans were done within 4.5 hours of symptom onset and repeated at 24 hours post-thrombolysis. An emergency NCCT would be performed for deteriorating neurological deficits.
Expected results This should include information about the likely outcome of the protocol (for example, likely yield of protein, typical microscopy images, etc.). We encourage authors to include one set of data from an experiment that worked using the protocol. If applicable, include advice on how to interpret and analyze raw data	SHR1 might demonstrate an independent association with fatal outcomes in AIS patients treated with rt-PA, exhibiting superior predictive ability over other glucose metrics.
Ethics declarations	The study received ethical approval from the human research ethics committee of Saraburi Hospital on January 30, 2023 (Certificate No. EC004/2566).
Supporting information The protocol in PDF format available from protocols.io must be provided as Supporting Information file 1, with the caption: S1: Step-by-step protocol, also available on protocols.io	-
Acknowledgements	We thank Miss Dollapas Punpanich at the Bioscience Research and Development Center, Phramongkutklao Hospital for providing advice and analyzing statistical data. Furthermore, we would like to thank the Clinical Research Center, Faculty of Medicine, Thammasat University, for their assistance with the language editing service.
Authors' contributions	All authors have made substantial contributions to this work and have approved the final version of the manuscript. Concept and design: SK. Acquisition of data:

	SK. Statistical analysis: SK. Interpretation of data: SK and CK. Writing original draft: SK and CK. Writing review and editing: SK and CK.
References	[1] Tiamkao S, Pearkao C, Yubolchit N. Can stroke fast track improve quality of life of patients with acute ischemic stroke? J Med Assoc Thail. 2020;103(6):35-41. [2] Suwanwela NC. Stroke epidemiology in Thailand. J Stroke. 2014 Jan;16(1):1-7. doi: 10.5853/jos.2014.16.1.1. Epub 2014 Jan 31. [3] Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. [4] Kruyt ND, Biessels GJ, Devries JH, Roos YB. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol. 2010 Mar;6(3):145-55. doi: 10.1038/nrneurol.2009.231. [5] MacDougall NJ, Muir KW. Hyperglycaemia and infarct size in animal models of middle cerebral artery occlusion: systematic review and meta-analysis. J Cereb Blood Flow Metab. 2011 Mar;31(3):807-18. doi: 10.1038/jcbfm.2010.210. [6] Roberts GW, Quinn SJ, Valentine N, Alhawassi T, O'Dea H, Stranks SN, et al. Relative Hyperglycemia, a Marker of Critical Illness: Introducing the Stress Hyperglycemia Ratio. J Clin Endocrinol Metab. 2015 Dec;100(12):4490-7. doi: 10.1210/jc.2015-2660. [7] Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008 Aug;31(8):1473-8. doi: 10.2337/dc08-0545. Epub 2008 Jun 7. Erratum in: Diabetes Care. 2009 Jan;32(1):207. [8] Zhu B, Pan Y, Jing J, Meng X, Zhao X, Liu L, et al. Stress Hyperglycemia and Outcome of Non-diabetic Patients After Acute Ischemic Stroke.

Front Neurol. 2019 Sep 18;10:1003. doi: 10.3389/fneur.2019.01003.

[9] Li J, Quan K, Wang Y, Zhao X, Li Z, Pan Y, et al. Effect of Stress Hyperglycemia on Neurological Deficit and Mortality in the Acute Ischemic Stroke People With and Without Diabetes. Front Neurol. 2020 Sep 24;11:576895. doi:10.3389/fneur.2020.576895.

[10] Merlino G, Smeralda C, Gigli GL, Lorenzut S, Pez S, Surcinelli A, et al. Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis. J Thromb Thrombolysis. 2021 Apr;51(3):789-797. doi: 10.1007/s11239-020-02252-y.

[11] Yang CJ, Liao WI, Wang JC, Tsai CL, Lee JT, Peng GS, et al. Usefulness of glycated hemoglobin A1c-based adjusted glycemic variables in diabetic patients presenting with acute ischemic stroke. Am J Emerg Med. 2017 Sep;35(9):1240-1246. doi: 10.1016/j.ajem.2017.03.049.

[12] Chen X, Liu Z, Miao J, Zheng W, Yang Q, Ye X, et al. High Stress Hyperglycemia Ratio Predicts Poor Outcome after Mechanical Thrombectomy for Ischemic Stroke. J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1668-1673. doi:10.1016/j.jstrokecerebrovasdis.2019.02.022.

[13] Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211.

[14] Ngiam JN, Cheong CWS, Leow AST, Wei YT, Thet JKX, Lee IYS, et al. Stress hyperglycaemia is associated with poor functional outcomes in patients with acute ischaemic stroke after intravenous thrombolysis. QJM. 2022 Jan 21;115(1):7-11. doi: 10.1093/qjmed/hcaa253.

[15] Chen G, Ren J, Huang H, Shen J, Yang C, Hu J, et al. Admission Random Blood Glucose, Fasting Blood Glucose, Stress Hyperglycemia Ratio, and

Functional Outcomes in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis. Front Aging Neurosci. 2022 Feb 8;14:782282. doi: 10.3389/fnagi.2022.782282.

[16] Lee TF, Drake SM, Roberts GW, Bersten A, Stranks SN, Heilbronn LK, et al. Relative Hyperglycemia Is an Independent Determinant of In-Hospital Mortality in Patients With Critical Illness. Crit Care Med. 2020 Feb;48(2):e115-e122. doi: 10.1097/CCM.0000000000004133.

[17] Roberts G, Sires J, Chen A, Thynne T, Sullivan C, Quinn S, et al. A comparison of the stress hyperglycemia ratio, glycemic gap, and glucose to assess the impact of stress-induced hyperglycemia on ischemic stroke outcome. J Diabetes. 2021 Dec;13(12):1034-1042. doi: 10.1111/1753-0407.13223.

[18] Jo K, Bajgur SS, Kim H, Choi HA, Huh PW, Lee K. A simple prediction score system for malignant brain edema progression in large hemispheric infarction. PLoS One. 2017 Feb 8;12(2):e0171425. doi: 10.1371/journal.pone.0171425.

[19] Al-Buhairi AR, Jan MM. Recombinant tissue plasminogen activator for acute ischemic stroke. Saudi Med J. 2002 Jan;23(1):13-9.